Beyond GLP-1: What Amylin Analogs Could Mean for the Next Generation of Weight-Loss Drugs
A hormone your pancreas already makes is now at the center of some of the most promising obesity drug trials in years.
Great — I now have rich, real data from PubMed, ClinicalTrials.gov, and news sources. Let me write the article.
GLP-1s changed the conversation around obesity drugs. But the next chapter might be written by a hormone most people have never heard of.
Amylin is a small peptide your pancreas releases alongside insulin every time you eat. Its job: slow digestion, suppress glucagon, and — critically — signal your brain that you're full. According to a 2006 paper in Physiology & Behavior, amylinergic control of food intake is a distinct satiety pathway, separate from GLP-1. That matters because hitting two different satiety systems at once may do more than either one alone.
The drug class built around this hormone is called amylin analogs. Right now, they're one of the most active areas in obesity pharmacology — and a few are deep into Phase 3 trials.
What Amylin Actually Does in Your Brain
When you eat a meal, amylin is released from beta cells in your pancreas and travels to the brainstem, where it activates receptors that reduce appetite and slow the rate at which your stomach empties. A 2026 study in Molecular Metabolism found that pancreatic amylin dynamically reconfigures distributed brain networks governing appetite regulation in mice — meaning it doesn't just flip one switch, it reshapes how multiple brain regions talk to each other around food.
People with obesity often have blunted amylin signaling. The idea behind amylin analogs is to restore and amplify that signal pharmacologically.
The first approved amylin analog was pramlintide (brand name Symlin), used as an injectable add-on for type 1 and type 2 diabetes. But pramlintide required multiple daily injections and had modest weight effects on its own. The newer generation of long-acting analogs — designed for once-weekly dosing — is a different animal.
Cagrilintide: The One Furthest Along
The most-studied next-gen amylin analog is cagrilintide, developed by Novo Nordisk. A 2024 review in Cardiology Reviews described cagrilintide as a long-acting amylin analog for the treatment of obesity, noting its once-weekly subcutaneous dosing and its favorable early efficacy and tolerability profile.
The real excitement, though, is what happens when you combine it with semaglutide — the GLP-1 in Wegovy. The combination, called CagriSema, hit the New England Journal of Medicine in August 2025 with two simultaneous Phase 3 readouts:
- The REDEFINE 1 trial studied CagriSema in adults with overweight or obesity (without diabetes).
- The REDEFINE 2 trial studied it in adults with overweight or obesity and type 2 diabetes.
Both were published in NEJM on August 14, 2025. A subsequent systematic review and meta-analysis in the American Journal of Cardiology pooled the CagriSema randomized controlled trial data and found that CagriSema outperformed semaglutide monotherapy for weight reduction — though the authors noted the evidence was assessed using GRADE methodology and quality ratings should be considered when interpreting results.
Novo Nordisk currently has multiple active Phase 3 trials running. ClinicalTrials.gov shows a long-term weight loss and maintenance study of CagriSema in obesity and a separate Phase 3 trial for cagrilintide monotherapy — neither yet approved by the FDA, meaning these are still investigational medicines.
Eloralintide: Eli Lilly's Entry
Novo Nordisk isn't the only player. Eli Lilly has developed eloralintide (LY3841136), described in Molecular Metabolism in 2025 as a novel amylin receptor agonist — from discovery to clinical proof of concept. Unlike cagrilintide, eloralintide is designed to be more selective for the amylin receptor rather than also hitting calcitonin receptors.
In December 2025, the Lancet published a 48-week Phase 2 randomized controlled trial of eloralintide — a multicentre, double-blind, placebo-controlled study evaluating its weight loss efficacy and safety profile. Phase 1 proof-of-concept data were also published in Diabetes, Obesity and Metabolism in early 2026.
And there's a third contender: petrelintide, which completed a Phase 2 trial comparing dose levels versus placebo for obesity and overweight with comorbidities, per ClinicalTrials.gov.
A 2026 network meta-analysis in Endocrinology, Diabetes & Metabolism specifically looked at novel amylin-based therapies for weight management in adults without diabetes — pooling data across these emerging agents to compare their relative efficacy.
Why a Dual-Mechanism Approach Makes Sense
GLP-1 agonists primarily work through gut-brain signaling via the vagus nerve and GLP-1 receptors in the hypothalamus. Amylin works differently — through brainstem receptors and a distinct neural circuit. According to a 2024 expert review in Expert Review of Clinical Pharmacology, amylin analogs for obesity without diabetes represent both a present and future opportunity, with the combination approach being particularly promising because the two pathways appear to be additive rather than redundant.
A 2025 systematic review in Pharmacological Reviews on emerging pharmacotherapies for obesity placed amylin analogs prominently in the next generation of treatments, alongside GIP/GLP-1 dual agonists and triple agonists.
The broader picture, as Nature reported in September 2025: the obesity drug market is evolving fast, and combination regimens hitting multiple satiety pathways simultaneously are a core part of where the science is heading.
What This Means for You
- Amylin analogs are not yet FDA-approved for obesity — cagrilintide, eloralintide, and petrelintide are all still in clinical trials. Nothing to ask your prescriber about yet, but worth tracking.
- CagriSema (cagrilintide + semaglutide) has Phase 3 data in NEJM — if you're already on or considering semaglutide, this combination is the most likely near-term option to watch.
- The "one drug" era may be ending. Just as cardiologists use combination therapy for blood pressure, obesity medicine appears to be moving toward multi-mechanism combinations. That's not a sign the current drugs don't work — it's how medicine matures.
Not medical advice. Talk to your prescriber about your specific situation, medications, and health history.
